Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 1054 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership MOST POPULAR Medical Cannabis Formulation May Be Capable of Killing Breast Cancer Cells,... May 21, 2021 Moxetumomab Approved by FDA for Hairy Cell Leukemia September 14, 2018 Conducting Phase I Clinical Trials During the COVID-19 Pandemic August 5, 2020 Patient Guide in Bladder Cancer Now Available Also in French April 28, 2026 Load more HOT NEWS The Appraisal – Scientific disruption: what is it, and do we... Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find... Withdrawal of Application for the EMA Marketing Authorisation of Infigratinib
